MAPK8IP3

Across TCGA pan-cancer cohorts, MAPK8IP3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MAPK8IP3 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MAPK8IP3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MAPK8IP3 expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

HNSC, LUAD, and PDAC are the cancer types where MAPK8IP3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.738	0.548	.017	11	view →
LUAD	OS	Tertile	All	0.468	0.818	.012	8	view →
PDAC	OS	Tertile	All	0.940	0.789	.023	7	view →
GBM	DFS	Median	All	0.845	0.647	.015	3	view →
CCRCC	DFS	Median	All	1.000	0.686	.045	2	view →
LSCC	DFS	Quartile	III,IV	0.355	0.850	.043	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MAPK8IP3–HNSC (DFS)

Open the HNSC breakdown →